background
asthma
major
public
health
problem
huge
social
econom
burden
affect
million
peopl
worldwid
viral
respiratori
infect
major
caus
acut
asthma
exacerb
may
contribut
asthma
incept
high
risk
young
children
suscept
genet
background
acut
exacerb
associ
decreas
lung
growth
acceler
loss
lung
function
add
substanti
cost
morbid
associ
asthma
discuss
import
prevent
viral
infect
well
establish
prevent
strategi
well
explor
good
person
hygien
handwash
avoid
cigarett
smoke
like
reduc
respiratori
viral
infect
eat
healthi
balanc
diet
activ
probiot
supplement
bacterialderiv
product
may
reduc
recurr
infect
suscept
children
practic
antivir
therapi
current
avail
suitabl
widespread
use
summari
hand
hygien
best
measur
prevent
common
cold
healthi
balanc
diet
activ
probiot
supplement
immunostimul
may
reduc
recurr
infect
asthmat
children
asthma
major
public
health
problem
huge
social
econom
burden
affect
million
peopl
worldwid
viral
respiratori
infect
major
caus
acut
asthma
exacerb
contribut
asthma
incept
high
risk
young
children
suscept
genet
background
histori
wheez
associ
respiratori
viral
infect
earli
life
one
major
risk
factor
later
develop
asthma
togeth
sensit
aeroallergen
earli
life
famili
histori
asthma
allergi
reflect
genet
predisposit
respiratori
viral
infect
also
princip
caus
asthma
exacerb
children
adult
howev
question
whether
viral
infect
select
suscept
host
whether
viral
infect
may
induc
asthma
de
novo
damag
airway
settl
word
virus
caus
simpli
unmask
asthma
respiratori
virus
first
infect
nasal
epitheli
cell
trigger
antivir
respons
respons
driven
type
iii
interferon
ifn
induc
follow
recognit
viral
ribonucl
acid
rna
pattern
recognit
receptor
prr
tolllik
receptor
tlr
cell
surfac
endosom
prr
whilst
rna
helicas
receptor
rigi
nodlik
receptor
detect
viral
rna
cytoplasm
signal
via
prr
activ
transcript
factor
lead
product
secret
type
iii
ifn
ifn
bind
cell
surfac
receptor
activ
separ
pathway
lead
product
interferon
stimul
gene
isg
encod
antivir
protein
combat
infect
well
prr
transcript
factor
amplifi
ifn
product
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
human
rhinoviru
hrv
singl
strand
rna
virus
engag
differ
cell
signal
pathway
airway
epitheli
cell
rsv
hmpv
rna
primarili
detect
rigi
cytoplasm
rsv
also
detect
hrv
endocytos
epitheli
cell
therefor
primarili
detect
endosom
earli
infect
process
rigi
later
infect
follow
upregul
prr
fusion
f
protein
rsv
recognis
epitheli
cell
surfac
success
antivir
respons
would
see
infect
limit
upper
airway
case
clinic
major
viral
infect
healthi
individu
respons
defici
predominantli
upperairway
viral
infect
hrv
may
spread
lower
airway
caus
lower
respiratori
symptom
exacerb
asthma
predispos
individu
definit
data
yet
produc
experiment
hrv
infect
adult
volunt
initi
suggest
asthmat
like
develop
lower
respiratori
infect
lri
healthi
adult
e
less
like
abl
limit
viral
replic
upper
airway
subsequ
vitro
infect
primari
airway
epitheli
cell
asthmat
healthi
adult
hrv
demonstr
asthmat
cell
produc
less
make
potenti
suscept
infect
slower
clear
infect
suscept
virusinduc
cell
cytotox
defici
respons
peripher
blood
mononuclear
cell
plasmacytoid
dendrit
cell
asthmat
adult
children
also
observ
particular
studi
respons
rsv
hrv
influenza
like
overal
impair
innat
immun
respons
asthmat
airway
epithelium
result
defici
antivir
respons
epitheli
cell
immun
cell
childhood
especi
infanc
character
developmentallyregul
defici
innat
adapt
immun
defici
like
increas
risk
viral
lri
children
especi
high
risk
asthma
allergi
year
end
summer
parent
asthmat
children
concern
acut
asthma
exacerb
follow
common
cold
ask
minim
risk
winter
viral
season
valid
concern
asthmat
children
intermitt
wheez
mostli
symptomat
viral
infect
asthmat
exacerbationpron
phenotyp
suscept
acut
exacerb
requir
hospit
unschedul
visit
medic
attent
major
risk
factor
acut
exacerb
includ
previou
acut
exacerb
allergi
young
age
poorli
control
asthma
particular
viral
respiratori
infect
moreov
recent
data
suggest
interact
allergi
viral
infect
occur
increas
risk
asthma
exacerb
acut
exacerb
associ
decreas
lung
growth
acceler
loss
lung
function
add
substanti
cost
morbid
associ
asthma
viral
respiratori
infect
main
caus
asthma
exacerb
children
major
risk
factor
admiss
hospit
everi
autumn
hrv
common
viral
agent
respiratori
tract
virus
detect
children
asthma
exacerb
includ
rsv
influenza
coronaviru
hmpv
parainfluenza
viru
adenoviru
bocaviru
current
drug
prevent
treatment
virusinduc
exacerb
asthma
poorli
effect
novel
altern
therapi
need
much
research
interest
focus
potenti
role
respiratori
viral
infect
play
incept
asthma
well
establish
hospit
rsv
bronchiol
risk
factor
asthma
childhood
epidemiolog
studi
shown
increas
risk
asthma
lri
caus
hrv
childhood
origin
asthma
coast
birth
cohort
studi
wheez
rsv
odd
ratio
hrv
hrv
rsv
associ
increas
asthma
risk
age
six
year
childhood
asthma
studi
ca
perth
australia
show
wheez
hrv
rsv
first
year
life
risk
factor
current
wheez
five
year
age
infant
birth
four
month
winter
viru
peak
carri
highest
risk
develop
asthma
compar
birth
month
peak
risk
asthma
increas
sever
lri
slri
especi
presenc
allerg
sensit
earli
life
appear
synergist
interact
viral
infect
allerg
sensit
suggest
two
hit
model
induct
persist
asthma
data
also
provid
seri
novel
strategi
primari
prevent
asthma
prevent
either
allerg
sensit
slri
high
risk
children
strategi
also
support
studi
simo
et
al
use
palivizumab
prevent
rsv
infect
decreas
risk
recurr
wheez
nonatop
prematur
infant
crucial
period
respect
asthma
initi
appear
first
two
three
year
life
growth
remodel
lung
airway
proce
maximum
rate
pulmonari
inflamm
result
atopi
slri
occur
vulner
time
hypothes
perturb
underli
tissu
differenti
program
result
deleteri
long
term
effect
respiratori
function
result
widespread
belief
amongst
paediatr
respiratori
commun
intervent
measur
lower
frequenc
andor
intens
slri
earli
life
amongst
high
risk
atop
subgroup
children
like
success
prevent
asthma
success
strategi
would
major
implic
reduc
high
impact
chronic
diseas
commun
recent
studi
use
cultureindepend
techniqu
challeng
longheld
dogma
lung
steril
demonstr
microbiota
commun
exist
lung
implic
new
data
clear
howev
new
concept
research
requir
resid
microbiom
differ
presenc
respiratori
diseas
therefor
interact
respiratori
virus
resid
pulmonari
microbiom
postul
pulmonari
gastrointestin
microbiota
influenc
immun
system
intervent
approach
bacteri
immunostimul
prebiot
andor
probiot
creat
healthi
gut
respiratori
microbiota
potenti
strategi
prevent
viral
infect
children
import
vector
hrv
transmiss
famili
member
particularli
sibl
hrv
shed
peak
two
four
day
infect
decreas
sharpli
thereaft
although
nasal
sampl
posit
rhinoviru
five
week
symptomat
infect
three
way
common
cold
transmiss
children
first
inhal
small
particl
aerosol
cough
second
larg
particl
droplet
saliva
expel
sneez
third
selfinocul
one
conjunctiva
nasal
mucosa
touch
person
object
contamin
cold
virus
first
two
method
ineffici
third
import
method
transmiss
mode
transmiss
could
differ
age
index
case
durat
contact
factor
moreov
evid
daili
activ
infect
peopl
lead
contamin
environment
surfac
hrv
eg
light
switch
telephon
dial
button
handset
meticul
hand
hygien
best
measur
prevent
common
cold
frequent
hand
wash
avoid
touch
one
nose
eye
use
alcoholbas
hand
sanit
also
effect
promot
handwash
associ
reduct
respiratorytract
infect
cold
childcar
centr
usa
canada
australia
decreas
absenc
due
respiratori
ill
school
set
hand
hygien
campaign
also
success
reduc
absente
caus
influenzalik
ill
among
schoolchildren
egypt
similar
program
within
famili
would
expect
reduc
transmiss
hrv
famili
member
recent
cochran
review
includ
data
randomis
control
trial
observ
studi
investig
effect
physic
intervent
reduc
spread
respiratori
virus
author
conclud
respiratori
viru
spread
reduc
hygien
measur
handwash
especi
around
younger
children
reduc
transmiss
children
famili
member
controversi
still
exist
newli
publish
studi
show
antivir
hand
treatment
use
adult
volunt
recruit
univers
commun
significantli
reduc
rv
infect
rvrelat
common
cold
ill
asthmat
children
avoid
close
contact
peopl
cold
especi
first
three
day
ill
littl
evid
support
effect
face
mask
reduc
risk
viral
respiratori
infect
consequ
use
mask
gener
recommend
prevent
common
cold
immun
function
antivir
defens
number
compon
specif
nonspecif
asthmat
children
improv
immun
function
follow
simpl
advic
includ
healthi
life
style
regular
exercis
balanc
diet
adequ
sleep
avoid
environment
tobacco
smoke
stress
unnecessari
antibiot
exercis
antiinflammatori
effect
long
term
protect
develop
chronic
diseas
obes
regular
exercis
moderateintens
associ
reduc
incid
upper
respiratori
tract
infect
howev
long
hour
intens
train
appear
make
children
suscept
upper
respiratori
tract
infect
recommend
mean
aerob
exercis
walk
optim
frequenc
three
five
day
week
optim
durat
minut
continu
activ
recent
studi
iga
secret
rate
neg
correl
incid
infect
recent
random
trial
compar
medit
exercis
waitlist
control
among
adult
age
year
older
found
signific
reduct
ari
ill
malnutrit
common
caus
immun
defici
worldwid
balanc
diet
fundament
healthi
immun
system
vitamin
defici
associ
increas
risk
infect
earlylif
wheez
reduc
asthma
control
vitamin
deriv
involv
regul
immun
system
tissu
inflamm
well
prevent
respiratori
infect
zinc
selenium
trace
element
necessari
function
innat
adapt
immun
function
high
intak
fruit
veget
ensur
adequ
consumpt
nutrient
antioxid
appear
benefici
asthma
although
recent
review
shown
zinc
garlic
echinacea
purpurea
ginseng
supplement
sever
month
may
reduc
cold
incid
insuffici
evid
recommend
vitamin
miner
supplement
manag
asthmat
children
without
nutrient
defici
howev
larg
control
trial
show
echinacea
ineffect
reduc
infect
rate
symptom
sever
hrv
infect
healthi
young
adult
volunt
vitamin
c
supplement
fail
reduc
incid
cold
gener
popul
except
expos
short
period
extrem
physic
stress
final
worth
rememb
infant
breastf
significantli
higher
risk
respiratori
gastrointestin
infect
breast
milk
biolog
activ
substanc
contain
antimicrobi
immunomodulatori
element
sleep
circadian
system
exert
regulatori
influenc
immun
function
sleep
depriv
affect
immun
function
sever
way
includ
reduc
natur
killer
cell
activ
suppress
product
increas
level
circul
proinflammatori
cytokin
also
evid
enhanc
suscept
common
cold
pneumonia
poor
sleep
effici
air
pollut
nitrogen
dioxid
ozon
particul
matter
environment
tobacco
smoke
et
long
correl
multipl
advers
effect
immun
system
suscept
viral
respiratori
tract
infect
children
studi
europ
unit
state
shown
children
live
smoker
approxim
twice
risk
contract
seriou
respiratori
tract
infect
earli
life
cigarett
smoke
lead
longer
durat
cough
greater
frequenc
abnorm
auscultatori
find
acut
respiratori
tract
ill
higher
risk
sever
exacerb
urinari
leukotrien
level
identifi
children
expos
et
high
risk
asthma
exacerb
strong
evid
pharmacolog
prepar
help
prevent
viral
infect
specif
effect
immun
system
result
promis
hope
use
strategi
attenu
role
virus
asthma
incept
ancient
physician
middl
east
prescrib
yogurt
cure
disord
stomach
intestin
stimul
appetit
written
old
persian
testament
abraham
owe
longev
consumpt
sour
milk
popular
probiot
intestin
microbiota
significantli
increas
nobel
prizewin
russian
scientist
eli
metchnikoff
suggest
long
life
bulgarian
peasant
result
consumpt
ferment
milk
product
term
probiot
mean
life
use
live
microorgan
typic
bifidobacterium
lactobacillu
speci
administ
adequ
amount
confer
benefici
physiolog
effect
host
prebiot
nutrient
particular
oligosaccharid
foster
growth
probiot
colon
term
synbiot
use
product
contain
probiot
prebiot
trillion
bacteria
differ
speci
colon
human
gut
microbiota
particip
host
metabol
vitamin
synthesi
control
epitheli
cell
growth
protect
infecti
microb
help
proper
develop
function
immun
system
constant
crosstalk
microbiota
gutassoci
lymphoid
tissu
largest
lymphoid
tissu
human
bodi
contain
bodi
lymphocyt
establish
mucos
immun
toler
gut
common
mucos
immun
describ
phenomenon
immun
cell
especi
regulatori
tcell
traffic
influenc
respons
mucos
surfac
includ
lung
alter
microbiota
composit
dysbiosi
result
immunolog
dysregul
may
underli
mani
human
diseas
inflammatori
diseas
obes
allergi
autoimmun
reduc
bacteri
divers
infant
gastrointestin
tract
associ
increas
risk
allerg
sensit
allerg
rhiniti
asthma
atop
dermat
first
year
life
especi
first
week
microbiota
newborn
highli
variabl
critic
time
postnat
matur
immun
system
microbiota
shape
genet
environment
factor
includ
mode
deliveri
neonat
born
mean
vagin
deliveri
expos
mother
gut
skin
vagin
flora
breast
feed
diet
farm
urban
live
vitamin
statu
antibiot
consumpt
knowledg
stimul
interest
use
probiot
prebiot
intent
introduct
encourag
specif
microb
shape
immun
system
develop
specif
microbiota
activ
distinct
tolerogen
dendrit
cell
gut
interact
drive
regulatori
tcell
differenti
modul
respons
insid
outsid
gut
probiot
success
use
treatment
sever
gastrointestin
disord
viral
antibioticassoci
diarrhea
inflammatori
bowel
diseas
howev
attempt
prevent
treat
allerg
disord
eczema
asthma
allerg
rhiniti
inconsist
result
grow
number
clinic
trial
use
probiot
prevent
manag
respiratori
infect
precis
mechan
larg
unknown
specul
includ
probiot
compet
pathogen
increas
barrier
function
respiratori
epithelium
immunostimulatori
effect
enhanc
cellular
immun
increas
activ
natur
killer
cell
macrophag
airway
probiot
reduc
frequenc
gastrointestin
respiratori
tract
infect
children
attend
day
care
centr
also
found
reduc
incid
ventilatorassoci
pneumonia
respiratori
infect
healthi
hospit
children
reduc
durat
common
cold
symptom
one
studi
demonstr
daili
probiot
supplement
six
winter
month
children
three
five
year
age
reduc
incid
fever
cough
rhinorrhea
notabl
advers
event
probiot
combin
vitamin
miner
also
reduc
durat
sever
common
cold
recent
cochran
review
randomis
control
trial
show
probiot
better
placebo
reduc
number
episod
acut
upper
respiratori
infect
uri
reduc
antibiot
use
differ
mean
durat
episod
increas
advers
event
probiot
food
probiot
milk
yogurt
function
food
contain
welldefin
probiot
strain
may
reduc
risk
catch
common
cold
repres
simpl
safe
effect
avail
afford
method
prevent
respiratori
infect
children
although
sever
clinic
trial
show
prevent
effect
probiot
prebiot
synbiot
treatment
respiratori
infect
studi
posit
fail
show
signific
prevent
effect
explain
differ
result
clinic
trial
particular
import
point
immunomodulatori
capabl
probiot
straindepend
differ
dosag
durat
intervent
popul
environment
background
may
also
affect
result
one
major
limit
field
possibl
test
probiot
particular
prepar
technic
advanc
requir
appar
discrep
result
studi
resolv
sever
immunostimul
includ
herbal
extract
bacteri
extract
synthet
compound
promot
increas
immun
defenc
respiratori
tract
recent
cochran
review
includ
data
placebocontrol
trial
includ
particip
age
year
variou
type
immunostimul
use
reduc
acut
respiratori
tract
infect
involv
either
upper
lower
airway
author
conclud
immunostimul
reduc
incid
acut
respiratori
infect
averag
suscept
children
trial
qualiti
gener
poor
high
level
statist
heterogen
evid
subgroup
analysi
focus
bacteri
immunostimul
includ
produc
similar
result
lower
statist
heterogen
bv
bronchovaxom
immunostimul
extract
eight
common
bacteri
pathogen
upper
respiratori
tract
haemophilu
influenza
diplococcu
pneumonia
klebsiella
pneumonia
ozaena
staphylococcu
aureu
streptococcu
pyogen
viridan
neisseria
catarrhali
use
sever
countri
around
world
long
year
recent
studi
show
bv
reduc
number
acut
respiratori
infect
compar
placebo
children
histori
recurr
infect
particular
interest
razi
et
al
show
children
age
one
six
year
recurr
wheez
given
bv
reduct
rate
wheez
subsequ
month
compar
placebo
p
addit
durat
wheez
attack
two
day
shorter
group
given
bv
group
given
placebo
p
direct
evid
mechan
involv
lack
human
studi
howev
recent
data
rodent
show
baselin
regulatori
lymphocyt
activ
airway
boost
microbederiv
stimul
gut
bacteri
immunostimul
also
shown
enhanc
innat
immun
ie
intensif
phagocytosi
adapt
immun
discuss
evid
exist
impair
innat
immun
respons
respiratori
viral
infect
asthmat
entri
rhinoviru
normal
epitheli
cell
initi
vigor
innat
immun
respons
secret
apoptosi
induct
asthma
respons
impair
result
viral
replic
cell
cytotox
enhanc
virion
shed
increas
suscept
common
cold
epitheli
cell
asthmat
patient
respond
exogen
treatment
exhibit
reduc
rhinoviru
releas
cakebread
xu
et
al
jackson
syke
et
al
propos
defici
type
iii
contribut
asthma
exacerb
correct
defici
exogen
interferon
would
logic
approach
advantag
interferon
applic
includ
broad
spectrum
activ
low
risk
resist
develop
prophylact
intranas
recombin
shown
effect
rhinoviru
infect
human
result
clinic
trial
await
interest
howev
system
symptom
associ
sever
viral
infect
eg
influenza
associ
interferon
care
dose
may
requir
consid
occurr
local
side
effect
neutropenia
cost
use
longterm
prophylaxi
daili
intranas
administr
interferon
feasibl
howev
random
clinic
trial
use
similar
strategi
current
underway
adult
chronic
respiratori
diseas
result
keenli
await
vitamin
defici
common
worldwid
problem
besid
import
bone
health
vitamin
play
import
role
adequ
function
innat
adapt
immun
system
includ
develop
dendrit
cell
regulatori
lymphocyt
product
antimicrobi
protein
airway
epithelium
modifi
effect
intestin
flora
inflammatori
disord
modul
inflammatori
respons
viral
infect
recent
report
suggest
vitamin
might
play
role
recent
increas
allerg
diseas
vitamin
insuffici
associ
higher
incid
respiratori
tract
infect
wheez
ill
children
reduc
asthma
control
emerg
depart
visit
sever
asthma
exacerb
hospit
recent
studi
children
five
year
age
newli
diagnos
asthma
vitamin
supplement
northern
hemispher
winter
month
septemb
juli
prevent
declin
serum
concentr
oh
reduc
risk
asthma
exacerb
trigger
acut
respiratori
tract
infect
macrolid
possess
antiinflammatori
immunomodulatori
properti
extend
beyond
antibacteri
activ
inde
attenu
proinflammatori
cytokin
product
bronchial
epitheli
cell
neutrophil
macrophag
may
contribut
clinic
improv
mani
patient
chronic
airway
inflamm
azithromycin
antirhinovir
activ
reduc
hrv
replic
releas
increas
interferon
product
epitheli
cell
macrolid
antibiot
inhibit
rsv
infect
human
airway
epitheli
cell
three
week
treatment
clarithromycin
rsv
bronchiol
statist
signific
effect
hospit
length
stay
rate
readmiss
hospit
within
six
month
discharg
howev
direct
evid
macrolid
prevent
respiratori
viral
infect
children
lack
major
respiratori
viral
infect
young
children
caus
hrv
rsv
briefli
discuss
antivir
strategi
prevent
hrv
rsv
infect
asthmat
children
serotyp
hrv
antivir
drug
consid
effect
vaccin
antivir
agent
design
inhibit
rhinoviru
attach
entri
cell
viral
uncoat
rna
protein
synthesi
tabl
show
intervent
strategi
target
variou
step
infect
process
hrv
icosahedr
shape
capsid
form
ident
copi
viral
capsid
structur
protein
capsid
protect
singlestrand
posit
sens
rna
genom
hrva
b
often
induc
selflimit
upper
respiratori
infect
recent
discov
hrvc
associ
slri
infant
bronchiol
asthma
exacerb
children
prevent
attach
entri
uncoat
hrv
deposit
nasal
conjunctiv
mucosa
transport
posterior
nasopharynx
mucociliari
action
epitheli
cell
socal
major
group
hrv
use
intercellular
adhes
receptor
minor
group
attach
low
densiti
lipoprotein
ldl
receptor
veryldl
vldl
receptor
epitheli
cell
adenoid
area
bind
enter
cell
viral
attach
prevent
specif
antihrv
neutral
antibodi
antireceptor
antibodi
solubl
receptor
molecul
endotheli
cell
express
histamin
receptor
increas
adhes
molecul
express
demonstr
histamin
infus
secondgener
decreas
express
cultur
bronchial
epitheli
cell
zinc
may
also
act
antivir
agent
reduc
level
monoclon
antibodi
cellular
effect
coldsol
nasal
spray
multival
fab
fusion
protein
better
avid
vitro
potenc
hrv
tremacamra
solubl
intercellular
adhes
molecul
reduc
sever
experiment
rhinoviru
infect
pleconaril
oral
administ
antivir
drug
act
bind
hydrophob
pocket
viral
protein
stabil
protein
capsid
viru
releas
rna
genom
target
cell
outcom
clinic
trial
pleconaril
reveal
mix
result
new
compound
current
develop
despit
extens
research
agent
approv
prevent
andor
therapi
rhinovirusinduc
diseas
far
ruprintrivir
select
inhibit
hrv
proteas
show
potent
broadspectrum
antihrv
activ
vitro
ruprintrivir
nasal
spray
solut
prophylaxi
reduc
proport
subject
posit
viral
cultur
reduc
viral
titer
decreas
frequenc
cold
hrv
rna
synthesi
replic
block
deoxyribozym
morpholino
oligom
small
interf
ribonucl
acid
novel
antivir
therapi
discov
recent
may
one
day
add
significantli
armamentarium
antivir
agent
respiratori
viral
infect
asthmat
children
maternallyderiv
rsv
neutral
antibodi
help
protect
infant
rsv
hospit
palivizumab
humanis
monoclon
antibodi
rsv
fusion
protein
effect
rsv
wheez
children
reduc
hospit
highrisk
individu
rsv
prophylaxi
palivizumab
significantli
reduc
rel
risk
subsequ
recurr
wheez
nonatop
prematur
infant
motavizumab
anoth
monoclon
antibodi
rsv
approxim
increas
abil
neutral
rsv
fold
increas
abil
reduc
viral
titer
compar
palivizumab
motavizumab
also
found
superior
palivizumab
reduc
outpati
medic
attend
lower
respiratori
ill
vaccin
hrv
rsv
develop
quit
time
safe
effect
vaccin
present
high
rate
exposur
virus
earli
life
presenc
serotyp
hrv
presenc
matern
antibodi
risk
vaccin
induc
diseas
rel
immatur
infant
immun
system
make
effect
vaccin
difficult
respiratori
viral
infect
major
contributor
global
burden
impos
asthma
earli
life
contribut
incept
asthma
respons
acut
exacerb
asthma
childhood
debat
complet
settl
children
high
risk
develop
asthma
establish
asthma
may
increas
risk
acquir
respiratori
viral
infect
may
less
abl
contain
upper
airway
sever
simpl
gener
strategi
use
help
prevent
respiratori
viral
infect
asthmat
children
tabl
good
person
hygien
handwash
avoid
cigarett
smoke
like
reduc
respiratori
viral
infect
gener
immunostimulatori
strategi
eat
healthi
balanc
diet
activ
probiot
supplement
bacterialderiv
product
eg
may
reduc
recurr
infect
suscept
children
research
continu
specif
antivir
therapi
includ
vaccin
current
avail
practic
therapi
suitabl
widespread
use
role
prevent
strategi
primari
prevent
asthma
high
risk
children
consider
academ
interest
number
studi
current
pipelin
result
await
interest
author
declar
compet
interest
author
contribut
ha
pd
conceiv
design
review
author
review
articl
abstract
data
particip
data
synthesi
ha
pd
ysc
draft
current
manuscript
critic
review
pd
cmj
author
contribut
read
approv
final
manuscript
